Licenses tau antibody to Sanofi in KRW 1.4 trillion deal
Next target: ApoE4... "Big Pharma due diligence complete"

Adel, which drew attention last year after licensing out an Alzheimer's disease drug candidate for KRW 1.4 trillion, is seeking a KOSDAQ listing with its central nervous system (CNS) antibody technology that "selectively targets only diseased proteins."


Adel's key competitive advantage is its strategy of "anticipating Big Pharma's next move and preparing in advance." A prime example is its experience licensing out a tau antibody it had developed in anticipation of Alzheimer's drug investment shifting from amyloid beta to tau.


As its next target, Adel has focused on the greatest genetic risk factor for Alzheimer's disease and is discussing a licensing deal with Big Pharma for an antibody that selectively targets it. The company also plans to prepare antibodies against aging-related proteins, blood-diagnostic antibodies, and a brain-delivery platform in advance, using the same approach, and to grow into a global CNS drug development company through recurring licensing deals.


ADEL CEO Yoon Seungyong speaks at an IPO briefing held at the Hanwha Financial Center in Yeongdeungpo-gu, Seoul, on the 18th. Photo by Park Jeongyeon.

ADEL CEO Yoon Seungyong speaks at an IPO briefing held at the Hanwha Financial Center in Yeongdeungpo-gu, Seoul, on the 18th. Photo by Park Jeongyeon.

View original image

Adel CEO Yoon Seungyong outlined this growth strategy at an initial public offering (IPO) press briefing held at the Hanwha Financial Center in Yeongdeungpo-gu, Seoul, on November 18.


Adel is a developer of treatments for neurodegenerative brain diseases that spun off from the University of Ulsan College of Medicine and Asan Medical Center in 2016. It divides the causes of Alzheimer's disease into three categories: pathology (tau), genetics (ApoE4), and aging (beta-2 microglobulin, or beta2m), and has secured an antibody candidate for each. All three candidates were designed to target only disease-causing forms of proteins without affecting their normal forms.


Its first achievement is ADEL-Y01, a tau antibody. Alzheimer's disease is caused by amyloid beta accumulating outside brain cells and tau clumping inside them and killing the cells. According to Adel, competing tau antibodies in clinical trials also bind to normal tau, whereas ADEL-Y01 binds only to acetylated tau (acK280), a modified form that increases in people with Alzheimer's disease. "Because treatments are administered repeatedly over a long period, there are far fewer safety concerns when they do not attack normal proteins," Yoon said.


In December 2025, ADEL-Y01 was licensed to Sanofi in a deal worth a total of $10.4 billion (approximately KRW 1.4 trillion). The upfront payment, which is non-refundable, was $80 million (approximately KRW 106.6 billion). ADEL-Y01, which has completed a Phase 1a clinical trial in the United States, is being prepared for subsequent clinical trials by Sanofi. "If development proceeds smoothly, it could be launched in the mid-to-late 2030s," Yoon said.


Yoon emphasized that the ADEL-Y01 deal resulted from anticipating the direction of new drug development. He said Adel had prepared a tau antibody ahead of time, having predicted that Big Pharma's investment would shift from amyloid beta to tau. He added that the company had also anticipated which targets Big Pharma would need in three or five years and secured the relevant candidates and data packages in advance. "A licensing deal can be concluded only if the pipeline is ready when Big Pharma needs it," Yoon said confidently.


The next key pipeline candidate is ADEL-Y04, an ApoE4 antibody. ApoE is a protein that transports cholesterol in the brain and has three forms: E2, E3, and E4. According to Yoon, people with the E4 gene are 8 to 12 times more likely to develop Alzheimer's disease. E3 and E4 differ by just one amino acid, at position 112, and Adel has secured an antibody that distinguishes between them and binds only to E4. The company is conducting due diligence with a global Big Pharma company and aims to license out the candidate in 2027.


ADEL-Y03, which targets aging, is designed to bind beta2m, a protein that increases in the blood with age and impairs cognitive function. It leaves beta2m bound to the normal immune protein MHC-I untouched and targets only beta2m that has separated from it. The company is also considering expanding its potential indications to heart, liver, and lung diseases.


Adel is also developing ADEL-D05, a blood-diagnostic antibody that determines the stage of Alzheimer's disease, and ADEL-BTS, a platform that helps antibodies cross the blood-brain barrier (BBB) and reach specific areas of the brain. The company plans to license both technologies to other companies on a non-exclusive basis.



Adel plans to offer 2.17 million shares at an indicative price range of KRW 18,000 to KRW 25,000 per share. The retail subscription period is November 23-24, and the company is expected to list in early December. "We will grow into a CNS drug development company through recurring licensing deals," Yoon said.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing